Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...
This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full text component.
More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...
The major challenge in prostate cancer screening is not just to find more cancer cases, but to identify the cancers that are ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, announced today that data from two significant phase III clinical trials using its ...
A next-generation Stockholm3 blood test detected aggressive prostate cancer more accurately than PSA, improving early ...
Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...
Clinical characteristics and long-term outcomes of extreme responders to first line treatment of metastatic prostate cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers ...
A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for ...
Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care The OPTIMA study is a prospective, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results